Shanghai Pharmaceuticals Holding Co., Ltd. (HKG: 2607, SHA: 601607) has announced the completion of data analysis from the Phase II study for its drug candidate I037, used in the treatment of acute ischemic stroke (AIS). LT3001 is recognized as a first-in-class AIS therapy that combines targeted thrombolysis with neuroprotective functions in the brain.
Partnership with Lumosa Therapeutics
In November 2019, SPH entered into a licensing agreement with Taiwan-headquartered Lumosa Therapeutics, securing exclusive rights for the development, manufacturing, and marketing of LT3001 in mainland China. This partnership underscores Shanghai Pharmaceuticals’ commitment to advancing innovative stroke therapies.
Safety and Preliminary Efficacy of LT3001
The Phase II study results indicated that LT3001 exhibited good overall safety and tolerability. The incidence of adverse events and reactions within 90 days post-initial administration was comparable across the high-dose LT3001 group, low-dose LT3001 group, and the placebo group, with the majority of these events being mild to moderate in severity. Additionally, the proportion of subjects achieving mRS scores of 0-1 on the 90th day following treatment demonstrated preliminary efficacy of the drug.-Fineline Info & Tech
